This article is more than 5 years old. Information may no longer be current.
Alcon introduces chewable eye vitamin
Click Here to Manage Email Alerts
Alcon, a division of Novartis, announced the launch of a chewable vitamin to support eye health in people with age-related macular degeneration.
The vitamin, Systane ICaps, is formulated based on results from the Age-Related Eye Disease Study 2 (AREDS2) research group. The company said in a press release that it is the first chewable vitamin based on the study and has lower zinc levels and no beta-carotene, compared to previous vitamins.
The Systane ICaps vitamins contain the following per serving: 500 mg of vitamin C, 400 IU of vitamin E, 25 mg of zinc, 2 mg of copper, 10 mg of lutein and 2 mg of zeaxanthin.
“The launch of Systane ICaps Chewable AREDS2 Eye Vitamin builds on the success Alcon’s ICaps line of eye vitamin formulations, which are designed to support healthy eyes,” Jeff Huffman, marketing director at Alcon, said in the release. “This is a significant step forward in the Alcon eye vitamin portfolio and extends the range of patients whose eye health needs can be met by our products, while also offering a flavorful, convenient chewable formula.”